Gieseler F, Biersack H, Brieden T, Manderscheid J, Nüssler V
Ann Hematol. 1994;69 Suppl 1:S13-7. doi: 10.1007/BF01757349.
In order to interact with topoisomerase II and induce genotoxicity, anthracyclines have to cross the outer cell membrane and the cytoplasm, enter the nucleus, and bind to the DNA. We incubated sensitive and resistant hematopoietic cells from cell lines and patient cells with daunorubicin, idarubicin, and its active derivative idarubicinol, extracted the anthracyclines from whole cells and nuclei, and determined their concentration fluorimetrically. Additionally, the DNA binding of the drugs was evaluated in the same cells by determining fluorescence resonance energy transfer between the anthracyclines and DNA-bound Hoechst dye 33342. We found a several thousand-fold accumulation of anthracyclines in sensitive and resistant hematopoietic cells; 30-60% of the drugs are found in the nucleus, resulting in 200- to 300-fold differences in concentration between the nucleus and outer fluids. A small proportion of the intracellular or intranuclear anthracyclines is bound to the DNA. The amount of DNA-bound anthracyclines correlates directly to cell death. It takes an additional 10 min for idarubicin and 30 min for daunorubicin to satisfy DNA binding sites after the drugs have arrived in the nucleus. The described methods provide the means to perform ex vivo studies on clinical material.
为了与拓扑异构酶II相互作用并诱导基因毒性,蒽环类药物必须穿过细胞膜外层和细胞质,进入细胞核,并与DNA结合。我们用柔红霉素、伊达比星及其活性衍生物伊达比星醇孵育细胞系来源的敏感和耐药造血细胞以及患者细胞,从全细胞和细胞核中提取蒽环类药物,并通过荧光法测定其浓度。此外,通过测定蒽环类药物与DNA结合的Hoechst染料33342之间的荧光共振能量转移,评估了相同细胞中药物与DNA的结合情况。我们发现敏感和耐药造血细胞中蒽环类药物有数千倍的积累;30%-60%的药物存在于细胞核中,导致细胞核与细胞外液之间的浓度差异达200至300倍。细胞内或细胞核内一小部分蒽环类药物与DNA结合。与DNA结合的蒽环类药物量与细胞死亡直接相关。在药物进入细胞核后,伊达比星还需要额外10分钟、柔红霉素还需要30分钟才能占据DNA结合位点。所述方法为对临床材料进行体外研究提供了手段。